recent publications
-
academic article
- Zeng, Y., Huebener, N., Fest, S., Weixler, S., Schroeder, U., Gaedicke, G., Xiang, R., Schramm, A., Eggert, A., Reisfeld, R. A., Lode, H. N. Fractalkine (cx3cl1)- and interleukin-2-enriched neuroblastoma microenvironment induces eradication of metastases mediated by t cells and natural killer cells Cancer Research 2007 67:2331-2338 DOI:10.1158/0008-5472.can-06-3041 PMID:17332365
- Zeng, Y., Jiang, J., Huebener, N., Wenkel, J., Gaedicke, G., Xiang, R., Lode, H. N. Fractalkine gene therapy for neuroblastoma is more effective in combination with targeted il-2 Cancer Letters 2005 228:187-193 DOI:10.1016/j.canlet.2005.01.057 PMID:15953676
- Niethammer, A. G., Wodrich, H., Loeffler, M., Lode, H. N., Emmerich, K., Abdollahi, A., Krempien, R., Debus, J., Huber, P. E., Reisfeld, R. A. Multidrug resistance-1 (mdr-1): A new target for t cell-based immunotherapy FASEB Journal 2005 19:158-159 DOI:10.1096/fj.04-2355fje PMID:15498893
- Neal, Z. C., Yang, J. C., Rakhmilevich, A. L., Buhtoiarov, I. N., Lum, H. E., Imboden, M., Hank, J. A., Lode, H. N., Reisfeld, R. A., Gillies, S. D., Sondel, P. M. Enhanced activity of hu14.18-il2 immunocytokine against murine nxs2 neuroblastoma when combined with interleukin 2 therapy Clinical Cancer Research 2004 10:4839-4847 DOI:10.1158/1078-0432.ccr-03-0799 PMID:15269160
- Neal, Z. C., Imboden, M., Rakhmilevich, A. L., Kim, K. M., Hank, J. A., Surfus, J., Dixon, J. R., Lode, H. N., Reisfeld, R. A., Gillies, S. D., Sondel, P. M. Nxs2 murine neuroblastomas express increased levels of mhc class i antigens upon recurrence following nk-dependent immunotherapy Cancer Immunology Immunotherapy 2004 53:41-52 DOI:10.1007/s00262-003-0435-2 PMID:14504825
- Schroeder, U., Bernt, K. M., Lange, B., Wenkel, J., Jikai, J., Shabat, D., Amir, R., Huebener, N., Niethammer, A. G., Hagemeier, C., Wiebusch, L., Gaedicke, G., et al. Hydrolytically activated etoposide prodrugs inhibit mdr-1 function and eradicate established mr-1 multidrug-resistant t-cell leukemia Blood 2003 102:246-253 DOI:10.1182/blood-2002-07-2268 PMID:12623853
- Pertl, U., Wodrich, H., Ruehlmann, J. M., Gillies, S. D., Lode, H. N., Reisfeld, R. A. Immunotherapy with a posttranscriptionally modified DNA vaccine induces complete protection against metastatic neuroblastoma Blood 2003 101:649-654 DOI:10.1182/blood-2002-02-0391 PMID:12393580
- Wrasidlo, W., Gaedicke, G., Guy, R. K., Renaud, J., Pitsinos, E., Nicolaou, K. C., Reisfeld, R. A., Lode, H. N. A novel 2 '-(n-methylpyridinium acetate) prodrug of paclitaxel induces superior antitumor responses in preclinical cancer models Bioconjugate Chemistry 2002 13:1093-1099 DOI:10.1021/bc0200226 PMID:12236791
- Xiang, R., Primus, F. J., Ruehlmann, J. M., Niethammer, A. G., Silletti, S., Lode, H. N., Dolman, C. S., Gillies, S. D., Reisfeld, R. A. A dual-function DNA vaccine encoding carcinoembryonic antigen and cd40 ligand trimer induces t cell-mediated protective immunity against colon cancer in carcinoembryonic antigen-transgenic mice Journal of Immunology 2001 167:4560-4565 PMID:11591784
- Niethammer, A. G., Xiang, R., Ruehlmann, J. M., Lode, H. N., Dolman, C. S., Gillies, S. D., Reisfeld, R. A. Targeted interleukin 2 therapy enhances protective immunity induced by an autologous oral DNA vaccine against murine melanoma Cancer Research 2001 61:6178-6184 PMID:11507070
- Shabat, D., Lode, H. N., Pertl, U., Reisfeld, R. A., Rader, C., Lerner, R. A., Barbas, C. F. In vivo activity in a catalytic antibody-prodrug system: antibody catalyzed etoposide prodrug activation for selective chemotherapy Proceedings of the National Academy of Sciences of the United States of America 2001 98:7528-7533 DOI:10.1073/pnas.131187998 PMID:11404472 PMCID:PMC34702
- Pertl, U., Luster, A. D., Varki, N. M., Homann, D., Gaedicke, G., Reisfeld, R. A., Lode, H. N. Ifn-gamma-inducible protein-10 is essential for the generation of a protective tumor-specific cd8 t cell response induced by single-chain il-12 gene therapy Journal of Immunology 2001 166:6944-6951 PMID:11359856
- Xiang, R., Silletti, S., Lode, H. N., Dolman, C. S., Ruehlmann, J. M., Niethammer, A. G., Pertl, U., Gillies, S. D., Primus, F. J., Reisfeld, R. A. Protective immunity against human carcinoembryonic antigen (cea) induced by an oral DNA vaccine in cea-transgenic mice Clinical Cancer Research 2001 7:856S-864S PMID:11300483
- Lode, H. N., Pertl, U., Xiang, R., Gaedicke, G., Reisfeld, R. A. Tyrosine hydroxylase-based DNA-vaccination is effective against murine neuroblastoma Medical and Pediatric Oncology 2000 35:641-646 DOI:10.1002/1096-911x(20001201)35:6<641::aid-mpo34>3.0.co;2-r PMID:11107137
- Balicki, D., Reisfeld, R. A., Pertl, U., Beutler, E., Lode, H. N. Histone H2A-mediated transient cytokine gene delivery induces efficient antitumor responses in murine neuroblastoma Proceedings of the National Academy of Sciences of the United States of America 2000 97:11500-11504 DOI:10.1073/pnas.210382997 PMID:11016973 PMCID:PMC17229
- Lode, H. N., Xiang, R., Pertl, U., Forster, E., Schoenberger, S. P., Gillies, S. D., Reisfeld, R. A. Melanoma immunotherapy by targeted IL-2 depends on CD4(+) T-cell help mediated by CD40/CD40L interaction Journal of Clinical Investigation 2000 105:1623-1630 DOI:10.1172/jci9177 PMID:10841521 PMCID:PMC300854
- Lode, H. N., Xiang, R., Perri, P., Pertl, U., Lode, A., Gillies, S. D., Reisfeld, R. A. What to do with targeted il-2 Drugs of Today 2000 36:321-336 PMID:12861355
- Xiang, R., Lode, H. N., Chao, T. H., Ruehlmann, J. M., Dolman, C. S., Rodriguez, F., Whitton, J. L., Overwijk, W. W., Restifo, N. P., Reisfeld, R. A. An autologous oral DNA vaccine protects against murine melanoma Proceedings of the National Academy of Sciences of the United States of America 2000 97:5492-5497 DOI:10.1073/pnas.090097697 PMID:10779556 PMCID:PMC25856
- Lode, H. N., Reisfeld, R. A. Targeted cytokines for cancer immunotherapy Immunologic Research 2000 21:279-288 DOI:10.1385/ir:21:2-3:279 PMID:10852128
- Xiang, R., Lode, H. N., Gillies, S. D., Reisfeld, R. A. T cell memory against colon carcinoma is long-lived absence of antigen Journal of Immunology 1999 163:3676-3683 PMID:10490962
- Lode, H. N., Xiang, R., Duncan, S. R., Theofilopoulos, A. N., Gillies, S. D., Reisfeld, R. A. Tumor-targeted il-2 amplifies t cell-mediated immune response induced by gene therapy with single-chain il-12 Proceedings of the National Academy of Sciences of the United States of America 1999 96:8591-8596 DOI:10.1073/pnas.96.15.8591 PMID:10411920
- Lode, H. N., Moehler, T., Xiang, R., Jonczyk, A., Gillies, S. D., Cheresh, D. A., Reisfeld, R. A. Synergy between an antiangiogenic integrin alpha(v) antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases Proceedings of the National Academy of Sciences of the United States of America 1999 96:1591-1596 DOI:10.1073/pnas.96.4.1591 PMID:9990069
- Lode, H. N., Xiang, R., Becker, J. C., Gillies, S. D., Reisfeld, R. A. Immunocytokines: A promising approach to cancer immunotherapy Pharmacology & Therapeutics 1998 80:277-292 DOI:10.1016/s0163-7258(98)00033-3 PMID:9888698
- Dolman, C. S., Mueller, B. M., Lode, H. N., Xiang, R., Gillies, S. D., Reisfeld, R. A. Suppression of human prostate carcinoma metastases in severe combined immunodeficient mice by interleukin 2 immunocytokine therapy Clinical Cancer Research 1998 4:2551-2557 PMID:9796990
- Xiang, R., Lode, H. N., Dreier, T., Gillies, S. D., Reisfeld, R. A. Induction of persistent tumor-protective immunity in mice cured of established colon carcinoma metastases Cancer Research 1998 58:3918-3925 PMID:9731503
- Pertl, U., Xiang, R., Kleindienst, P., Becker, J. C., Gillies, S. D., Reisfeld, R. A., Lode, H. N. Tumor targeting with immunocytokines. A novel approach for cancer therapy Minerva Biotecnologica 1998 10:89-99
- Lode, H. N., Reisfeld, R. A., Handgretinger, R., Nicolaou, K. C., Gaedicke, G., Wrasidlo, W. Targeted therapy with a novel enediyene antibiotic calicheamicin theta(i)(1) effectively suppresses growth and dissemination of liver metastases in a syngeneic model of murine neuroblastoma Cancer Research 1998 58:2925-2928 PMID:9679947
- Dreier, T., Lode, H. N., Xiang, R., Dolman, C. S., Reisfeld, R. A., Kang, A. S. Recombinant immunocytokines targeting the mouse transferrin receptor: Construction and biological activities Bioconjugate Chemistry 1998 9:482-489 DOI:10.1021/bc980020e PMID:9667950
- Lode, H. N., Dreier, T., Xiang, R., Varki, N. M., Kang, A. S., Reisfeld, R. A. Gene therapy with a single chain interleukin 12 fusion protein induces t cell-dependent protective immunity in a syngeneic model of murine neuroblastoma Proceedings of the National Academy of Sciences of the United States of America 1998 95:2475-2480 DOI:10.1073/pnas.95.5.2475 PMID:9482910
- Lode, H. N., Xiang, R., Dreier, T., Varki, N. M., Gillies, S. D., Reisfeld, R. A. Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy Blood 1998 91:1706-1715 PMID:9473237
- Lode, H. N., Xiang, R., Varki, N. M., Dolman, C. S., Gillies, S. D., Reisfeld, R. A. Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow Journal of the National Cancer Institute 1997 89:1586-1594 DOI:10.1093/jnci/89.21.1586 PMID:9362156
- Xiang, R., Lode, H. N., Dolman, C. S., Dreier, T., Varki, N. M., Qian, X. Q., Lo, K. M., Lan, Y., Super, M., Gillies, S. D., Reisfeld, R. A. Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy Cancer Research 1997 57:4948-4955 PMID:9354462